Language

Leadership

 

 

Marie-Pierre Dubé, Ph.D., Director

Marie-Pierre Dubé is Associate Professor in the Department of Medicine at the Université de Montréal. She is the director of the Beaulieu-Saucier Pharmacogenomics Centre at the Montreal Heart Institute where she leads clinical research projects in pharmacogenomics and personalized medicine. Dr. Dubé completed a B.Sc. and Ph.D. in genetics at McGill University and post-doctoral studies in public health at University of Toronto. She worked at Xenon Pharmaceuticals before taking her current academic position. Dr Dubé has authored over 90 peer-reviewed articles, has received career awards from the FRSQ, and her research is funded by CIHR and Genome Canada.

 

 

 

Jean-Claude Tardif, M.D., Clinical Director

Director, Montreal Heart Institute Research Institute

Jean-Claude Tardif is a cardiologist and Director of the Research Centre at the Montreal Heart Institute and Professor of Medicine at the UofMontreal. Dr Tardif holds the Canada Research Chair in translational and personalized medicine and the UofM endowed research chair in atherosclerosis. He is the Scientific Director of the Montreal Heart Institute Coordinating Centre (MHICC) and Chairman of the steering committees of the Canadian Atherosclerosis Imaging Network (CAIN) and Medical Imaging Trials NEtwork of Canada (MITNEC).

Dr Tardif has authored > 800 articles and abstracts. His research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves animal models, mechanistic and observational studies and international randomized clinical trials. He has been the leader of several large clinical trials in the field of atherosclerosis and other CV diseases.

Dr Tardif has won multiple awards including the Research Achievement Award of the Canadian Cardiovascular Society, the Genesis Award of Bio-Québec and the Armand-Frappier Award of the Government of Quebec. Because of his accomplishments, Dr Tardif was named Fellow of the Canadian Academy of Health Sciences.